113 studies found for:    dengue
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
81 Completed Role of Andi-d in Dengue Fever: a Pilot Study
Condition: Dengue Fever
Intervention: Drug: anti-d
82 Recruiting Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
Condition: Dengue
Interventions: Biological: rDEN1Δ30;   Biological: Placebo;   Biological: rDEN2Δ30-7169
83 Active, not recruiting Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults
Condition: Dengue
Interventions: Biological: rDEN2Δ30-7169 vaccine;   Biological: Placebo
84 Completed Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine
Condition: Dengue Fever
Interventions: Biological: rDEN2/4delta30(ME) vaccine;   Biological: Placebo
85 Completed Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults
Condition: Dengue
Intervention: Biological: rDEN3-3'D4delta30
86 Recruiting Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
Condition: Dengue
Interventions: Biological: TetraVax-DV Vaccine - Admixture TV003;   Biological: TetraVax-DV Vaccine - Admixture TV005;   Biological: Placebo
87 Completed Implementation Research of New Dengue Vector Control Tools
Condition: DENGUE
Intervention: Other: Insecticide treated curtains and insecticide treated covers
88 Unknown  The Effect of Chloroquine in the Treatment of Patients With Dengue
Condition: Dengue
Interventions: Drug: Placebo;   Drug: Chloroquine
89 Completed Celgosivir as a Treatment Against Dengue
Condition: Dengue Fever
Interventions: Drug: celgosivir;   Drug: placebo
90 Completed Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)
Condition: Dengue
Interventions: Biological: Low-dose V180 with low-dose ISCOMATRIX™ adjuvant;   Biological: Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant;   Biological: Medium-dose V180 (non-adjuvanted);   Biological: Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant;   Biological: Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant;   Biological: Medium-dose V180 with Alhydrogel™ adjuvant;   Biological: High-dose V180 (non-adjuvanted);   Biological: High-dose V180 with low-dose ISCOMATRIX™ adjuvant;   Biological: High-dose V180 with medium-dose ISCOMATRIX™ adjuvant;   Biological: Low-dose V180 with high-dose ISCOMATRIX™ adjuvant;   Biological: Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant;   Biological: High-dose V180 with high-dose ISCOMATRIX™ adjuvant;   Biological: Placebo
91 Not yet recruiting Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults
Condition: Dengue
Intervention: Biological: TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.
92 Not yet recruiting Efficacy and Safety of Ivermectin Against Dengue Infection
Condition: Dengue Fever
Interventions: Drug: 2 days Ivermectin;   Drug: 3 days Ivermectin;   Drug: Placebo
93 Completed Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
Conditions: Acquired Bleeding Disorder;   Dengue Haemorrhagic Fever
Interventions: Drug: activated recombinant human factor VII;   Drug: placebo
94 Completed A Study of Balapiravir in Patients With Dengue Virus Infection
Condition: Dengue
Interventions: Drug: balapiravir [RO4588161];   Drug: placebo
95 Recruiting Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand
Condition: Dengue
Interventions: Biological: TV003;   Biological: Placebo for TV003
96 Active, not recruiting Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart
Condition: Dengue
Interventions: Biological: TV003 Vaccine;   Biological: Placebo Vaccine
97 Unknown  Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR
Conditions: Malaria;   Dengue;   Japanese Encephalitis
Interventions: Drug: 20% deet insect repellent;   Drug: placebo control
98 Recruiting A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
Conditions: Chikungunya Virus;   Dengue Virus
Intervention: Biological: INTERCEPT Platelets
99 Completed Phase 1b Study Investigating Safety & Immunogenicity of DENVax Given Intradermally by Needle or Needle Free PharmaJet Injector
Condition: Normal Healthy Adult
Interventions: Biological: DENVax;   Device: PharmaJet Injector
100 Active, not recruiting Sensitivity Study of Diagnostic for Early Detection of Dengue Infection
Condition: Infectious Diseases
Intervention:

First Page    Show previous page of results Previous Page (61-80) Studies Shown (81-100) Next Page (101-113) Show next page of results    Last Page
Indicates status has not been verified in more than two years